Tamboli Ajim 4

What Happened Ajim Tamboli, Chief Financial Officer of First Tracks Biotherapeutics, received a series of restricted stock unit (RSU) awards totaling 169,400 RSUs in grants dated April 21–23, 2026. The filings list four derivative acquisitions: 45,700 RSUs (4/21), 41,233 RSUs (4/21), 41,233 RSUs (4/22) and 41,234 RSUs (4/23). Each RSU is reported at $0.00 acquisition price (these are awards, not open‑market purchases), so no cash changed hands at grant.

Key Details

• Transaction dates/prices: Apr 21–23, 2026; all grants reported at $0.00 (code A = award/grant).
• Total granted: 169,400 RSUs (sum of the four grants).
• Shares owned after transaction: Not specified in the Form 4 provided.
• Footnotes of note:
  • F1: Each RSU converts to 1 share upon settlement for no consideration.
  • F2: Vesting for these RSUs — 1/4 vests on April 20, 2027, then 1/4 annually thereafter (subject to continued service).
  • F3: Describes a separate stock option vesting schedule (25% on April 20, 2027, then monthly over 48 months); this applies to options and is distinct from the RSU grants.
• Filing: Form 4 filed Apr 23, 2026 reporting transactions from Apr 21–23, 2026.

Context RSUs are compensation awards that convert into shares only when they vest and are settled; they are not immediate market purchases or sales. Such grants are common executive compensation and do not by themselves indicate the insider bought or sold stock in the open market. The listed vesting schedule means the shares will be delivered over multiple years subject to Tamboli’s continued service.